Abstract
Amyloid beta (A𝛽) plaque burden, as measured by positron emission tomography (PET), is increasingly being used as a biomarker for Alzheimer’s disease (AD) as well as a screening or monitoring tool for clinical trials with amyloid-lowering drugs. However, PET imaging is expensive, invasive and not widely available for all patients, necessitating alternative means to assess brain A𝛽 accumulation.
